Beyond Antibiotics: Why Precision Matters in the Fight Against AMR

Antimicrobial resistance (AMR) is one of the most urgent challenges facing both human and animal health today.

The World Health Organisation has warned that by 2050, drug-resistant infections could cause up to 10 million deaths annually. In agriculture, the routine use of antibiotics for growth promotion and disease prevention has contributed to this global issue, creating resistant bacterial strains that can move between animals, humans, and the environment.

To combat AMR effectively, the agricultural industry must embrace precision solutions that target pathogens without collateral damage. This is where phage therapy comes into its own. Each phage species infects only a specific bacterial host, meaning treatments can be designed to address a particular disease without affecting beneficial bacteria. This precise action not only improves treatment outcomes but also reduces the pressure that drives resistance in microbial populations.

Phage therapy complements responsible antibiotic use rather than replacing it entirely. When integrated into herd or flock health programs, phages can be used preventively or as an alternative treatment, reducing the overall antibiotic load. Combined with better biosecurity, vaccination, and nutritional management, phage therapy helps create a more resilient livestock system that aligns with the global “One Health” framework—recognising the interconnectedness of human, animal, and environmental wellbeing.

As global consumers, regulators, and exporters demand proof of antibiotic reduction, precision therapies like phages will play a vital role in maintaining both productivity and trust. In short, phage therapy is not just a scientific breakthrough—it’s a cornerstone of the future of responsible farming.